Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) grants compounding pharmacies an exemption from FDA premarket approval — meaning Strive can compound medications without an approved NDA — as long as four core conditions are met:

1. Compounded pursuant to a valid prescription for an individually identified patient.
2. Compounded by a licensed pharmacist or physician.
3. Not essentially a copy of a commercially available drug (unless on the FDA shortage list).
4. Bulk drug substances comply with USP/NF monographs or the FDA's 503A bulks list.

At Strive's scale, maintaining clear documentation that each preparation is patient-specific is critical. FDA can and does inspect 503A pharmacies that appear to be manufacturing rather than compounding.

Generally no — 503A prohibits compounding preparations that are "essentially a copy" of a commercially available drug. The key exception is drugs on the FDA shortage list, where compounding is permitted even if a commercial version exists.

This is a live compliance area given active litigation in the GLP-1 space (e.g., semaglutide). Always confirm with the CCO before launching any preparation that closely mirrors a commercially available drug. The "not essentially a copy" determination is fact-specific and must be documented in a risk assessment.

Yes. Every compounded preparation must be pursuant to a valid prescription for a specific, individually identified patient. Batch compounding for anticipated prescriptions — without individual prescriptions in hand — is not permitted under 503A (it's a 503B concept). At Strive's volume, enterprise partnerships must be structured so that each prescription is patient-specific and traceable. This documentation is reviewed during FDA inspections.

503A applies to traditional compounding pharmacies — patient-specific prescriptions, not FDA-approved, exempt from premarket approval. 503B ("outsourcing facilities") may compound without individual prescriptions but must comply with full cGMP manufacturing requirements and FDA registration.

Strive currently operates as a 503A pharmacy. A 503B facility is planned (12–18 month horizon) and will operate under an entirely different regulatory framework. Do not conflate the two — the compliance requirements, documentation standards, and permitted activities are fundamentally different.

Reps operate under 503A advertising restrictions. Here's the practical guide:

When in doubt: talk about Strive's capabilities, not specific products. Never improvise compliance answers with enterprise partners — say "I'll get you a confirmed answer from our compliance team."

All three can apply simultaneously. A cleanroom compounding a hazardous sterile drug must comply with all three chapters.

The revised USP <797> (effective November 2023) defines two categories:

• Category 1: No sterility testing. Default BUDs: 12 hours at room temperature or 24 hours refrigerated.
• Category 2: Sterility testing, endotoxin testing, enhanced process controls. Allows extended BUDs based on stability data. Requires additional competency assessments and environmental monitoring rigor.

Most high-volume sterile compounding at Strive's scale targets Category 2 to support meaningful BUDs for patients and enterprise partners. Confirm Category 2 qualification with Quality before quoting BUDs to anyone.

Under USP <797>, ongoing environmental monitoring (EM) must include:

• Viable air sampling — active and passive (settle plates) in ISO-classified areas
• Non-viable air sampling — particle counts to verify ISO classification
• Surface sampling — gloved fingertip, equipment, and work surface swabs
• Temperature & humidity monitoring — continuous logging
• Pressure differential monitoring — ISO 7 buffer vs. ISO 8 ante vs. general room

Any excursion must trigger a documented investigation. Enterprise clients may request EM data as part of QA review — treat this documentation as partner-facing.

Yes — MFRs are required under both USP <795> and <797>. An MFR is the master recipe and must include: name/strength/dosage form, all ingredients and quantities, equipment and step-by-step procedure, in-process and final quality checks, assigned BUD, storage conditions, and the stability data or literature supporting the BUD.

Each individual preparation must also have a Compounding Record linked to the MFR documenting what actually happened during that specific batch.

No — with important nuance. Under 503A, Strive cannot advertise or promote specific compounded drug preparations to the general public. Strive can advertise its compounding services generally.

• ✅ Advertising compounding services, quality, and capabilities
• ✅ Provider-facing educational content on APIs and established science
• ✅ Website product pages (accepted risk — controlled visibility)
• ❌ Consumer advertising of specific compounded preparations
• ❌ Any implied claim of FDA approval
• ❌ Comparative claims to named brand-name drugs (Ozempic, Wegovy, Mounjaro, etc.)

Content in the GLP-1, weight loss, or hormone therapy category naming a specific API always requires an internal compliance check before publication.

Any specific statistic or clinical outcome figure must have a documented source on file before publication.

Per FTC 2023 guidance, all five of the following must be met:

1. Real patient with a documented identity on file
2. Signed HIPAA authorization and marketing release
3. Material connections disclosed on the face of the content
4. Claims in the testimonial are substantiated against documented outcomes
5. Atypical results must disclose what typical results are — "results may vary" alone is no longer sufficient

All patient testimonials require internal compliance review before publishing. Flag any testimonial making disease treatment claims for legal review.

Compliant response: "They contain the same active ingredient, but our product is a compounded preparation — not FDA-approved — prepared for patients with a documented need that the commercial product doesn't address."

Never say: "Yes, it's the same drug and works identically" or "Ours is actually more pure because it's made fresh" or "Ours is better because it's customized."

Comparing Strive's product to Ozempic, Wegovy, or any named brand — even favorably — is a hard compliance line and a Lanham Act litigation risk.

Yes, with conditions. Interstate distribution is permitted under 503A as long as Strive is licensed in both the sending and receiving state. Strive is currently licensed in all 50 states + DC — with sterile licensure pending in MN and SC. No sterile preparations may be shipped to those two states until licensure is complete.

States that have not signed the FDA Memorandum of Understanding (MOU) are subject to a 5% cap on interstate distribution from Strive. Always verify MOU status before scaling distribution into a new state market.

State board inspections can occur with limited notice. If a deficiency is found:

1. Notify the CCO and your compliance manager immediately
2. Preserve all inspection documentation — do not alter records
3. Respond within the timeframe specified in the inspection report
4. Document your corrective action with a CAPA — root cause, corrective action, preventive action, verification timeline
5. Escalate to legal counsel if the deficiency involves patient safety, product recall, or license jeopardy

Strive's inspection posture: compliant, calm, transparent. Acknowledge gaps with concrete mitigation plans. Inspectors respond better to proactive disclosure than defensiveness.

Enterprise partners apply cGMP-like QA expectations — documentation and quality systems that go beyond the minimum USP/503A floor. In practice:

• Documented quality management system (SOPs, deviation handling, CAPA process)
• Environmental monitoring data available on request
• Supplier qualification documentation for all bulk APIs
• Change control — partners expect notification of any formulation or process change
• Traceable, patient-specific batch records for every prescription fulfilled under the partnership
• Adverse event reporting pipeline and documentation

Strive's "503A pharmacy with a cGMP mindset" positioning is a commercial advantage. Treat enterprise QA audits as an opportunity to demonstrate maturity, not a compliance burden.

• Never make claims about specific compounded preparations in sales materials — reference Strive's capabilities and quality systems instead
• Every Rx must be patient-specific — enterprise deals must be structured around individual prescriptions, not bulk orders
• Don't quote BUDs without confirming with Quality — Category 1 vs. Category 2 BUDs differ significantly and are product-specific
• Price comparisons to brand drugs (Ozempic, Wegovy, etc.) are a hard stop — never do this in writing or in a recorded setting
• When a partner's QA team asks a question you're unsure about, say "I'll get you a confirmed answer from our compliance team" — do not improvise